Gemina Announces Closing of $910,000 Convertible Note Financing

VANCOUVER, BC / ACCESSWIRE / March 19, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that further to its news release dated February 22, 2024, it has raised gross proceeds of $910,000 under its non-brokered private placement (the "Private Placement") of unsecured convertible notes of the Company (the "Notes"). Please see the Company's news release dated February 22, 2024 for additional details regarding the terms of the Notes.

The proceeds from the Private Placement are intended to be used for general working capital and corporate purposes. All securities issued pursuant to the Private Placement are and will be subject to a four month hold period from the date of issue, expiring July 19, 2024, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

No finder's fees, commission, bonus, agent's options or other compensation was paid in connection with the Private Placement.

None of the securities sold under the Private Placement have been and will not be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

On Behalf of the Board of Directors

Brian Firth
Chief Executive Officer
Gemina Laboratories Ltd.

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable, and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, tuberculosis, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

For more information regarding the Company, please contact:

Gemina Laboratories Ltd

Brian Firth, Chief Executive Officer
Email: investor@geminalabs.com

SOURCE: Gemina Laboratories Ltd.